Isentress (Raltegravir)

Raltegravir inhibits the HIV‑1 integrase enzyme, specifically blocking the strand‑transfer step that inserts viral DNA into the host genome. By preventing this integration, the drug stops the formation of proviral DNA, thereby halting HIV replication and allowing the immune system to recover when used with other antiretrovirals.

The dose of Isentress is individualized by the prescribing healthcare professional based on factors such as the patient’s age, weight, renal function, and the composition of the accompanying antiretroviral regimen. No fixed dose is provided here; the prescriber sets the appropriate regimen.

Safety data for raltegravir in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss individual circumstances with the patient and consider alternative options when appropriate.

To order Isentress, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Isentress (raltegravir) was the first integrase strand transfer inhibitor approved and is known for a favorable safety profile and rapid viral suppression. Compared with newer agents such as dolutegravir, raltegravir may require twice‑daily dosing and has a lower barrier to resistance, but it remains an effective option for patients with specific resistance patterns.

Isentress tablets should be stored at room temperature, below 25 °C, in the original blister pack to protect them from moisture and light. Keep the product out of reach of children and avoid exposure to extreme heat or humidity, which could affect tablet integrity.

Isentress is taken orally, usually as a tablet swallowed with water. The exact dosing schedule—once or twice daily—depends on the prescriber’s instructions and the overall antiretroviral regimen. Patients should follow the healthcare provider’s guidance and not alter the dosing without medical advice.

Serious risks include severe allergic reactions such as anaphylaxis, liver toxicity indicated by elevated transaminases, muscle breakdown (rhabdomyolysis) with high creatine kinase levels, and rare but life‑threatening skin conditions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience symptoms such as rash, jaundice, muscle pain, or breathing difficulties.

Isentress should be avoided in individuals with known hypersensitivity to raltegravir or any of the tablet excipients. Caution is also advised for patients with severe renal impairment, uncontrolled liver disease, or those taking medications that significantly reduce raltegravir exposure, unless the prescriber determines the benefits outweigh the risks.